Crude and adjusted hazard ratios for the relation of the exposures (SBP and CIMT) and main confounders (DBP, ABI, and SBP) with the outcome (cardiovascular events).

<p>Crude and adjusted hazard ratios for the relation of the exposures (SBP and CIMT) and main confounders (DBP, ABI, and SBP) with the outcome (cardiovascular events).</p

Baseline characteristics of the example dataset of patients with manifest vascular disease.

<p>Baseline characteristics of the example dataset of patients with manifest vascular disease.</p

Relation between rs964184 (per minor allele) and lipid levels.

<p>Linear regression adjusted for age and sex.</p><p>*Additionally adjusted for lipid-lowering medication.</p

Association between body mass index and plasma log(TG), stratified by rs964184 genotype.

<p>Black line: CC genotype, red line: CG genotype, blue line: GG genotype. Dotted lines indicate 95% confidence interval.</p

Relation between minor allele frequencies and levels of plasma TG.

<p>Rs964184 minor allele frequency (95% confidence interval) at increasing levels of TG. N indicates the number of patients with a plasma TG level in this category.</p

Relation between rs964184 and risk of new vascular events.

<p>Hazard ratio (95% confidence interval) estimated with Cox proportional hazard models.</p><p>Model 1: adjusted for age and sex.</p><p>Model 2: Model 1 + triglyceride plasma level.</p

Relation between rs964184 genotype and presence of metabolic syndrome or being not at lipid treatment target.

<p>Logistic regression model, adjusted for age and sex.</p><p>*Number of patients with metabolic syndrome or LDL-cholesterol/nonHDL-cholesterol/apoB not at target level.</p><p>**Only in patients using lipid lowering medication.</p